Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Price, News & Analysis

TCR2 Therapeutics logo

About TCR2 Therapeutics Stock (NASDAQ:TCRR)

Advanced Chart

Key Stats

Today's Range
$1.48
$1.48
50-Day Range
$1.48
$1.98
52-Week Range
$0.82
$3.88
Volume
N/A
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TCRR Stock News Headlines

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
TCR2 Therapeutics Insider Trades Send a Signal
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
See More Headlines

TCRR Stock Analysis - Frequently Asked Questions

TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.06.

TCR2 Therapeutics (TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Vuzix (VUZI) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
11/10/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRR
CIK
1750019
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$151.82 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.81%
Return on Assets
-69.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.96
Quick Ratio
2.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
0.57

Miscellaneous

Outstanding Shares
39,260,000
Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:TCRR) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners